PEAR News and Press, Pear Therapeutics Inc. From 08/11/22

20% quarter-over-quarter revenue growth to $3.3 million Recent real-world health economic data for all three of Pear’s commercial products show cost-savings 1-3 Recent commercial formulary additions for reSET® and reSET-O® Pear Ther...

Somryst ® is the only FDA-authorized prescription digital therapeutic (PDT) for the treatment of chronic insomnia 24-month analysis showing $2,059 reduction in per-patient costs adds to the body of evidence to support the use of this PDT among people with chroni...

Pear Therapeutics ( NASDAQ: PEAR ) on Monday said its prescription digital therapeutic reSET-O for the treatment of opioid use disorder had been added to the SelectHealth healthcare plan. Utah-based SelectHealth provides health coverage to over 1M members across Utah, ...

SelectHealth teams with Pear to provide its members with covered access to Pear’s innovative prescription digital therapeutic (PDT), reSET-O ®, for the treatment of opioid use disorder (OUD) as adjunct to outpatient treatment that includes transmucosal buprenorphine ...

Pear Therapeutics' ( NASDAQ: PEAR ) opioid use disorder prescription digital therapeutic w ill be provided to Core Behavioral Health centers in the Tampa Bay, Fla., area. Cove will offer the reSET-O product in English and Spanish. reSET-O is a prescription cog...

Cove Behavioral Health will provide access to Pear’s reSET-O® to patients with opioid use disorder through a State Opioid Response (SOR) grant Cove, which serves over 30,000 individuals in the Tampa Bay community each year, will offer Pear’s reSET-O in...

Pear Therapeutics , Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), announced today that it will be added to the Russell US Index Series in conjunction with the September 2022 quarterly r...

Pear Therapeutics, Inc. (the “Company”) (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced it will issue its second quarter 2022 financial results after the close of mar...

Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the company will participate in Cowen’s 7th Annual FutureHealth Conference, a virtual event taking pl...

New Board Members Paul Mango, Shiva Rajaraman, and Tim Wicks bring a depth of experience and knowledge in both the healthcare and technology industries Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines calle...